A phase I study of vorinostat 1 and VEGFR inhibitor gefitinib 30 (Fig. 2) in combination therapy has been approved for targeting resistance by B cell chronic lymphocytic leukemia-lymphoma-like 11 gene (BIM) polymorphysim in EGFR mutant lung cancer (VICTORY-J) (NCT02151721). Here, EGFR is linked to lung cancer.